About us
About Pharmetheus
History
Mission & Values
Leadership
Scientific advisors
Our team
Social impact (CSR)
Science & Services
Contexts of use
Trial design and analysis
Program strategies and efficiences
Special/specific populations
Special considerations
Regulatory interactions
Pharmetheus Platforms
Model-Informed Drug Development
PBPK & PBBM
Pharmacometrics
QSP
Solutions
Milestone Analysis
Embedded Scientists
Expert Advice
Scientific Publication
Specific services
Model-Informed Bioequivalence & Biosimilarity
Accelerated submission
Concentration-QTc (C-QTc) modeling
Data-driven strategies for pediatric success
Training workshops
Publications
Case studies
Articles
Careers
Working with us
Open positions
Employee stories
Events
News
Contact us
Home
Publications
Model-informed fixed dosing of rozanolixizumab in gMG: PK/PD advantages and comparison with other FcRn blockers
Model-informed fixed dosing of rozanolixizumab in gMG: PK/PD advantages and comparison with other FcRn blockers
MIDD
Immunology
Pharmacometrics
CNS
PAGE 34 (2026) Abstr 11854
Lledó-García R, Björnsson MA